NCT05021731View on ClinicalTrials.gov

Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Latent TuberculosisKidney Failure
Interventions
DRUG

Rifampicin plus Isoniazid

Administration of rifampicin plus isoniazid for latent tuberculosis

DRUG

Rifapentine plus Isoniazid

Administration of rifapentine plus isoniazid for latent tuberculosis

DRUG

Rifampicin alone

Administration of rifampicin alone for latent tuberculosis

All Listed Sponsors
collaborator

Institut d'Investigació Biomèdica de Bellvitge

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Miguel Santín

OTHER

NCT05021731 - Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease | Biotech Hunter | Biotech Hunter